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Abstract
Among the different subsets of dendritic cells (DC), plasmacytoid dendritic cells (PDC) play a unique role in secreting large
amounts of type I interferons upon viral stimulation, but their efficiency as antigen-presenting cells has not been completely
characterized. We show here, by flow cytometry, with human primary blood PDC and with a PDC cell line, that PDC display
poor endocytic capacity for soluble or cellular antigens when compared to monocyte-derived myeloid DC. However,
immature PDC efficiently take up cellular material from live influenza-exposed cells, subsequently mature and cross-present
viral antigens very efficiently to specific CD8+ T cells. Therefore, during viral infection PDC not only secrete
immunomodulatory cytokines, but also recognize infected cells and function as antigen cross-presenting cells to trigger
the anti-viral immune response.
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Introduction
Antigen presenting cells (APC) play a crucial role in the
triggering and control of immune responses by their capacity to
take up and process antigens, and to efficiently activate naive or
memory T cells. Among APC, plasmacytoid dendritic cells (PDC)
constitute a special subset of dendritic cells (DC) [1,2], which were
originally described as the main producers of type I interferons in
viral infections [3,4] and initiate immune responses.
Human PDC express the intracellular pattern-recognition
receptors TLR7 and TLR9, allowing them to recognize viral or
bacterial genetic material. Indeed, single-stranded RNAs were
recently identified as natural ligands for TLR7/TLR8 [5,6],
whereas TLR9 recognizes unmethylated CpG oligonucleotides in
endosomes or lysosomes after their internalization[7,8]. Upon
TLR ligation by natural or artificial TLR agonists, activated PDC
secrete high amounts of IFNa, participating in the initiation of
immune activation. Moreover, they rapidly become cytotoxic by
acquiring TRAIL expression, so they can kill target cells
expressing DR4 or DR5[9], receptors which are up-regulated
upon viral infections[10]. Activated PDC are also involved in the
selective recruitment of effector cells for both innate and adaptive
immune responses[11].
PDC are able to differentiate into mature dendritic cells, when
cultured with IL-3 and CD40-L [12], or upon viral stimulation
[13]. Based on the initial stimulus, PDC stimulate allogeneic naı ¨ve
CD4+ T lymphocytes and induce their differentiation in either
Th2 [14], Th1 [15], IFNc/IL10 producing T cells [16], or IL-10
producing T regulatory cells[17]. However it remains unclear
whether they can prime a naı ¨ve T cell response [18,19], although
they can clearly restimulate anti-viral effector/memory CD4+ and
CD8+ T lymphocytes by direct presentation [20,21].
Besides direct priming, cross-priming is the mechanism of
stimulation of CD8+ T cells by APC presenting exogenously-
derived antigens; this is particularly important when viruses do not
infect APC. Cross-presentation involves different steps; i) endocy-
tosis of antigens, ii) their degradation and processing of the
generated peptides onto MHC class I molecules, and iii) the
expression of costimulatory molecules on APC surface. It has been
suggested that human PDC, compared to myeloid DC, have a
poor capacity to capture soluble or particulate antigen [12,22].
PDC may enhance myeloid DC-mediated cross-presentation by
means of IFNa secretion by PDC, which might favor this
mechanism[23], but PDC’s own ability to cross-present to CD8+
T cells is still a controversial and unresolved matter[24]. Indeed,
the scarcity of PDC in peripheral blood mononuclear cells
(0,5%)[25] and the difficulty to generate them in large numbers
in vitro [26] render their study difficult. We have recently
described a leukemic counterpart of PDC (LPDC for leukemic
PDC) [27], which displays similar phenotypic and functional
features to primary PDC [28]. A cell line has been generated from
fresh LPDC, as described previously [9], and by using this cell line
as a model, as well as primary PDC, we investigated endocytosis of
soluble and cellular antigens by PDC. Our study aimed also at
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up from whole cells during virus infection. Our data further
demonstrate the prominent role PDC play in viral infections.
Materials and Methods
Reagents and phenotypes
The medium used for cell culture was RPMI 1640 Glutamax
(GibcoBRL, Cergy-Pontoise, France) supplemented with 1 mM
sodium pyruvate, 20 mg/ml Gentamycin, non-essential amino
acids (referred to as complete medium), and 10% heat inactivated
Fetal Calf Serum (FCS, Gibco).
Immunophenotyping was performed by flow cytometry on a
FACScan (Becton Dickinson, Mountain View, CA) using direct or
indirect labelling. The following FITC-, PE- or biotin- conjugated
antibodies, as well as PC5-conjugated streptavidin, were pur-
chased from Immunotech (Marseille, France): CD1a (clone BL6),
CD4 (13B8.2), CD11b (Bear1), CD11c (BU15), CD18 (7B4),
CD19 (J4.119), CD20 (B9E9), CD32 (2 E 1), CD36 (FA6-152),
CD40 (mAb89), CD64 (22), CD80 (MAB104), CD83 (HB15A),
HLA-ABC (B9.12.1), DR (B8.12.2), CD16 (3G8), CD86
(HA5.2B7), MR (3.29.B1.10). Antibodies against CD1c (M241)
were purchased from Ancell, BDCA-2 (AC144), and BDCA-4
(AD5-17F6) from Miltenyi Biotech (Bergisch Gladbach, Ger-
many), avb3 (LM609) and avb5 (P1F6) from Chemicon
International (Temecula CA), CD1d (CD1d42) from Becton
Dickinson, DC-SIGN (120507) from (R&D system, Lille, France),
and CD123 (9F5) from Pharmigen (San Diego CA). The anti-
mouse FITC-conjugated antibodies CD91 (A2MRa-2) was
purchased from Dako (Glosgrup, Denmark).
Cell morphology was analyzed by microscopy on cytospins of
cell suspension after staining with May-Gru ¨nwald Giemsa (Kit Ral
555). IFNa was measured by ELISA (PBL biomedical laboratories,
Piscataway, NJ)
Cells
The cell line GEN3 was generated from leukemic PDC [27], as
described for the GEN2.2 cell line [9]. Tumor cells from the blood
of the patient GEN were seeded on irradiated adherent mouse
stromal cells (MS-5) in 10% FCS complete RPMI medium,
without any cytokine. This cell line has been growing for months
in our laboratory.
B lymphocytes were purified from healthy donors blood (B1 and
B2) or from spleen biopsies obtained from a patient with idiopathic
thrombocytopenic purpura (B3), by standard negative immuno-
magnetic selection with dynabeads (Dynal, Oslo, Norway).
Purified B lymphocyte suspension contained more than 95% B
cells, and were cryopreserved in liquid nitrogen and thawed
immediately before use. B cells were chosen as a model as they
represent a suitable target for influenza virus in vitro [29].
Myeloid dendritic cells (MoDC) were generated from mono-
cytes of HLA-A2*0201 healthy donors as described [30].
Monocytes were purified from fresh blood by Rosette Sep isolation
kit (Stem Cell Technologies, Meylan, France) and cultured for six
days in complete medium supplemented with 10% of FCS,
500 U/ml GM-CSF (Leucomax, Schering-Plough, France) and
10 ng/ml IL-4 (Tebu Bio, Le Perray-en-Yvelines, France). At the
end of the culture, MoDC were 100% CD1a+, CD14- and
CD83-.
We isolated primary PDC from blood of healthy donors by
using the positive selection BDCA-4 or BDCA-2 separator kit
(Miltenyi Biotech), following the instructions of the manufacturer.
The purity of enriched cell suspensions, was at least .90%, as
assessed by FITC-conjugated BDCA-2 or BDCA-4, and PE-
conjugated CD123. The immunophenotyping of PDC was done
either on purified PDC, or in PBMC after gating on the BDCA-2
positive population.
Endocytosis experiments
GEN3, primary PDC, or MoDC (0.5610
6 cells/ml) were
incubated with 1 mg/ml Lucifer Yellow (LY, for liquid phase
uptake) (Sigma Aldrich, Saint Quentin Fallavier, France), 0.1 mg/
ml FITC-conjugated Dextran (Dex, for carbohydrate endocytosis)
(MW 40,000-Molecular probes), and 0.1 mg/ml FITC-conjugated
Ovalbumin (OVA, for protein endocytosis) (Molecular probes) for
2 hours at 37uCo ra t4 uC. After two washes in ice-cold 2% FCS
HBSS (Hank’s Balanced Salt Solution, GibcoBRL), cells were
analyzed by flow cytometry. Mean fluorescence intensity (MFI)
values were calculated by subtracting MFI of cells incubated with
the tracers at 4uC, from the MFI at 37uC.
PKH 26 staining and phagocytosis assays
For phagocytosis assays, B cells (40610
6 cells/ml) were stained
with the lipophilic dye PKH26 (2 mM, (Sigma) (l emission =
576 nm)) following the indications of the manufacturer. After
staining, B cells were then prepared as described in a previous
work [31], in order to obtain apoptotic (c-irradiated cells,
137 Cs
source, 45 Gy), necrotic (heated for 45 min at 56uC), and
Rituximab-opsonized cells (1 mg/ml).
For treatment with virus, B cells were incubated overnight with
formaldehyde-inactivated influenza virus (strain A, New Caledo-
nia/20/99 IVR116 (H1N1), Aventis Pasteur, Val de Rueil,
France)(corresponding to 137 ng/ml hemagglutinin) in 10%
FCS complete RPMI supplemented with 10 ng/ml IL-4 (Tebu
Bio), and washed twice before use. These cells are further referred
to as ‘‘flu-B cells’’. A non-replicating virus was used throughout
this study, in order to avoid the production of new virus that could
interfere with cross-presentation experiments by directly infecting
the antigen presenting cells. This virus is able to enter into target
cells, since the nucleoprotein of the virus can be detected into the
cytoplasm of B cells after incubation with the virus [29]. The non-
infectious status of the virus was verified on eggs (data not shown).
In inhibition experiments, EDTA (2 mM), or cytochalasin D
(10 mM) were added. For GEN3 maturation, CpG 2336 (12,5 mg/
ml) (Coley Pharma, Ottawa Canada) was added for 24 h before
addition of B cells.
For endocytosis assessment, APC (0.5610
6 cells/ml) were co-
incubated for 2 hours at 37uCo r4 uC with PKH26-stained B cells
(0.75610
6 cells/ml). Endocytosis was stopped and conjugates were
dissociated by adding EDTA (2 mM) on ice. APC were then
stained: GEN3 with FITC-conjugated CD4 and CD36, MoDC
with FITC-conjugated CD11b, and primary PDC with FITC-
conjugated BDCA-2 and CD36. Simultaneously, B cells were
stained with PECy-5-conjugated CD19 and CD20. After washing,
PKH26 fluorescence was analyzed by flow cytometry gating on
FITC-labeled APC. CD19 and CD20 positive APC were excluded
from the analysis as they had likely formed conjugates with B cells
but had not necessarily internalized cellular material.
Evaluation of PDC maturation and IFNa secretion after
endocytosis
GEN3 or purified BDCA4+ PDC were incubated or not with
influenza virus for 24 hours, and cells were stained with FITC- or
PE-conjugated CD40, CD80, CCR7 or HLA I mAb. To check the
maturation and secretion of IFNa by PDC after contact with flu-B
cells, B cells were exposed or not to virus for 18 hours, washed,
and then incubated with GEN3 or purified BDCA4+ PDC. After a
PDC Cross-Present Viral Ag
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content was assessed by ELISA. Cells were stained with CD40,
CD80, CCR7 mAb, and maturation was accessed by flow
cytometry gating on GEN3 cells (according to their FSC/SSC
profile) or on PDC (labeled with BDCA2 plus BDCA4 biotinylated
mAb, and PeCy5-streptavidin).
Cross-presentation assay
We assessed cross-presentation by GEN3, and primary PDC by
measuring IFNc released by influenza-specific T cells. Influenza-
specific T cells were generated in one week-culture of purified
autologous CD8+ T lymphocytes activated by influenza-treated
and irradiated (30 Gy) HLA-A2+ MoDC [32,33]. These
influenza-specific cell lines contained 15 to 30% tetramer HLA-
A2/Flu58-66 positive specific T cells; their specificity was checked
using irrelevant and Flu-peptide pulsed T2 cells.
In the cross-presentation assay, allogeneic HLA-A2
neg B cells
were treated with the virus during 18 hours and then extensively
washed. In round-bottomed plates, in quadruplicates, 10
4 GEN3
or primary PDC (HLA-A2
pos) were co-incubated with 5610
3
irradiated (30Gy) B cells, treated or not with influenza virus, for
4 hours to allow endocytosis. 5610
5 influenza-specific T cells were
then added, and after 48 hours, culture supernatants were
recovered and their IFNc content was measured using Cytokine
Bead Array kit (Becton Dickinson, Le Pont de Claix, France)
following the manufacturer’s instructions.
Results
GEN3 is a PDC cell line derived from leukemic PDC
GEN3 cell line was generated from leukemic plasmacytoid
dendritic cells [27,34]according to the method previously de-
scribed[9]. They highly expressed CD123, BDCA-4, and CD40,
whereaswerenegative for CD80 and CD83 (Figure 1A). Incubation
with formaldehyde-inactivated influenza virus for 24 hours led to
their maturation: GEN3 cells up-regulated CD40, CD80, and
CD83 (Figure 1A), similarly to purified primary PDC (Figure 1B).
GEN3alsosecretedIFN-a (Figure1C),andacquiredadendriticcell
morphology (Figure 1D).
PDC express few endocytic receptors
We then evaluated the surface expression of molecules involved
in antigen capture (Figure 2). Primary PDC and GEN3 did not
express the Fc receptors CD16 nor CD64, whereas a low
expression of CD32 was detected. A weak expression of the C-
type lectin mannose receptor (MR) was detected on GEN3, but
not on primary PDC, whereas both primary PDC and GEN3 were
negative for DC-SIGN and Langerin (data not shown). The b2
integrin CD18, a subunit of the complement receptors CR3
(CD11b/CD18) and CR4 (CD11c/CD18) was highly expressed
by both primary PDC and GEN3, but CD11c and CD11b were
hardly detectable. CD91 and calreticulin are involved in the
uptake of apoptotic cells that are opsonized either with
complement, collectins (SP-A and SP-D) or with heat shock
proteins (review [35]). A low expression of CD91 was found on a
small subset of primary PDC but not on GEN3. avb3 and avb5
are two integrins implicated in the clearance of apoptotic cells by
DC and macrophages [32,36], in association with CD36. Both
GEN3 and primary PDC displayed a moderate expression of avb5
and a sharp expression of CD36. avb3 was present only on GEN3
cells. As a matter of comparison, the same phenotype was also
performed on monocyte-derived dendritic cells, and we found that
except for CD64, all the molecules studied were expressed on
MoDC, and such a wide range of endocytic receptors may favor
their ability to capture antigens. Conversely, PDC and GEN
displayed a very restricted set of endocytic receptors.
Endocytic capacity of PDC is weak
We assessed the ability of GEN3, primary PDC, and MoDC, to
endocytose soluble antigens by using Lucifer Yellow (LY), FITC-
conjugated Ovalbumin (OVA), and Dextran (Dex) (Figure 3A).
Both GEN3 and primary PDC engulfed LY and OVA with the
same efficiency, but less efficiently than MoDC (about ten-fold
highertracer capture was observed withMoDCcompared to PDC).
By contrast, primary PDC and GEN3 cells did not take up Dextran,
whereas MoDC efficiently captured this potential ligand for
mannose receptor.
We then evaluated the ability of PDC to take up cellular
material from apoptotic, necrotic, opsonized and non-treated cells,
in comparison to MoDC. To this end, we used a method that
allows the detection of endocytosis with a high sensitivity and
distinguishes between endocytosed or conjugated cells [29]. In
these experiments, endocytosis was measured by flow cytometry
using PKH26-labeled B-cells as target cells and appropriate FITC-
conjugated mAbs to identify APC (Figure 3B). Conjugates were
excluded using an additional labeling with PC5-conjugated CD19
and CD20. After 2 hours, at least half of the MoDC acquired
cellular material from B cells, whatever the B cell treatment. By
contrast, GEN3 remained PKH26
neg, whatever the condition,
suggesting their inability to capture opsonized or dead cells, or to
perform ‘‘nibbling’’ of cells.
PDC capture cellular material from influenza-treated cells
B e c a u s eP D Ca r ei n v o l v e di na n t i - v i r a li m m u n er e s p o n s e s ,w e
sought to determine whether GEN3 cells capture cellular antigens
from virus-infected cells. We used B cells incubated with formalde-
hyde-inactivated non-replicating influenza virus as a model of virus-
containing cells, henceforth referred to as ‘‘flu-B cells’’. As shown in
Figure 4A, cellular material from flu-B cells was efficiently taken up
b yG E N 3( 4 6a n d6 7 %o fG E N 3w e r eP K H 2 6
pos in the two
representative experiments shown). As expected, non-treated B cells
were not captured. Interestingly, primary purified BDCA4+ PDC
were also able to capture cellular material from flu-B cells (25 and
48% of PDC were PKH26
pos in the two representative experiments
shown) (Figure4B).So, PDC seems to specificallytake up cell-derived
material from virus-containing surrounding cells. Microscopic
observation of cell fluorescence showed that GEN3 took up small
membrane-containing fragments from virus-treated cells (Figure 4C).
This uptake of cellular material from flu-B cells required actin
polymerization and divalent cations, as demonstrated by inhibition of
uptakewithcytochalasinDandEDTA,respectively(Figure4D).This
endocytosis was not due to the capture of PKH26
pos vesicles such as
exosomes or other kinds of membrane shed particles. Indeed, when
GEN3 were incubated for two hours with the supernatant of 18-hour
flu-B cells culture, they remained PKH26
neg (Figure 4A).
To test whether cell maturation influenced this particular
endocytic capacity of PDC, we assessed capture after activation of
GEN3 cells with a TLR9 agonist. Figure 4E shows that in the
presence of CpG A (2336), the capacity of GEN3 cells to take up
cellular material from flu-B cells was inhibited, i.e. the percentage
of PKH26
pos GEN3 decreased from 45% (for immature GEN3) to
less than 10% (for mature GEN3).
Endocytosis of flu-B cells activates PDC and induces
cross-presentation of viral antigens
We next analyzed the consequences of flu-B cells capture on
PDC maturation. When GEN3 were directly treated with the
PDC Cross-Present Viral Ag
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(Figure 5A, upper panels), and HLA-I expression (data not
shown). Interestingly, after endocytosis of flu-B cells, GEN3 were
found activated to a similar extent (Figure 5A, lower panels).
Primary purified BDCA4+ PDC also matured after endocytosis of
flu-B-cells, upregulating CD40 and CD80 up to intensity
comparable to that observed after direct contact with the virus.
(Figure 5A, right panels). Therefore, PDC became activated
following the capture of cellular material from virus-treated cells.
Since the supernatant of flu-B cells did not induce the maturation
of PDC (data not shown) the involvement of free viral particles was
excluded. We also found significant IFNa secretion by GEN3 and
primary PDC after endocytosis of flu-B cells (Figure 5B).
We next analyzed the ability of PDC to activate influenza-specific
T cells. The activation of HLA-A2
pos influenza-specific CD8+ Tc e l l s
by both kinds of PDC was assessed by measuring IFNc release by T
cells. As expected, when virus-treated GEN3 (Figure 6A) or primary
purified BDCA2+ PDC (Figure 6B) were used, IFNc secretion was
observed, confirming the ability of PDC to perform direct
presentation of viral antigens. Cross-presentation of viral antigens
by PDC was then examined by incubating GEN3 or primary PDC
(both HLA-A2
pos) with B cells or flu-B cells (HLA-A2
neg), prior to
addition of T cells. Strikingly, GEN3 (Figure 6A) as well as primary
PDC (Figure 6B) pulsed with flu-B cells induced a highly significant
increase of IFNc secretion by T cells, when compared to non-treated
Bc e l l s( p ,0,005, student t test). This increase was not due to direct T
cell activation by flu-B cells, as flu-B cells alone did not induce any
IFNc increase. Moreover, T-cell activation driven by GEN3 pulsed
with the supernatant of 48h-virus-treated B cell culture was found
negative, ruling out the involvement of free viral particles. These data
demonstrate that PDC capture viral antigens from virus-exposed B
cells and subsequently cross-present these antigens to specific CD8+
T cells.This highly significant resultindicates a striking specific role of
PDC in activation of T cell responses in the context of viral infection.
Figure 1. Characterization of the GEN3 plasmacytoid dendritic cell line. The LPDC-derived cell line GEN3 or primary purified PDC were
incubated for 18 hours in the presence of formaldehyde-inactivated influenza virus. GEN3 cells (A) or primary PDC (B) were stained with indicated
mAb (open curves) or isotype control (filled curves) at day 0 (upper panels) and day 1 (lower panels). At day 1 production of IFNa by GEN3 was
measured by ELISA (C) (mean6SD of four experiments), and cell morphology was examined after May-Gru ¨ndwald Giemsa staining of cell cytospins
(D). Data are representative of 3 independent experiments.
doi:10.1371/journal.pone.0007111.g001
PDC Cross-Present Viral Ag
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PDC are involved early in innate phases of viral immunity
through the secretion of large amounts of IFNa[1,2], and TRAIL-
mediated cytotoxicity[9]. Previous studies have clearly established
that, upon exposure to viruses, PDC mature and acquire
costimulatory molecules (reviews[1,2]), so that infected PDC
become able to present viral antigens to CD8+ T cells[20,37].
These data suggested the involvement of PDC in the initiation of
adaptive immunity in the context of viruses that directly infect
PDC. Here, we evaluated the capacity of PDC to perform cross-
presentation, i.e. to acquire, process, and present exogenously-
derived antigens on HLA class I molecules to activate specific
CD8+ T cells[38]. The physiological essential function of cross-
presentation in viral infections has been demonstrated in the
context of immune responses to viruses that do not infect
APC[39]. Recent studies in human reported contradictory data
regarding the capacity of PDC to cross-present antigens[37,40].
We took advantage here of a cell line derived from leukemic
PDC (LPDC[27,28]), GEN3, as a model to study the uptake of
antigens by PDC, and their capacity for cross-presentation.
According to previous studies [22,41], PDC and GEN3 displayed
a weak capacity to capture dextran, which correlates with the
absence of mannose receptor and DC-SIGN expression, whereas
Figure 2. Assessment of the expression of receptors involved in antigen capture. Monocyte-derived dendritic cells (MoDC), GEN3 cells, and
primary blood BDCA2+ PDC were stained with indicated mAb (open curves) or isotype control (filled curves). Data are representative of two
independent experiments.
doi:10.1371/journal.pone.0007111.g002
PDC Cross-Present Viral Ag
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protein such as ovalbumin, although less efficiently when
compared to MoDC. We have shown that GEN3 expressed quite
the same pattern of endocytic receptors as primary PDC, the most
striking difference being the expression of avb3 on GEN3 but not
on primary PDC. On both cells, we found a weak expression of
CD32 (as previously described [42]), and a faint expression of
CD11b and CD11c. However, CD32 did not allow the capture of
Rituximab-opsonized cells by GEN3 albeit it was shown to
mediate the capture of immune complexes containing DNA in the
context of human lupus [43], or KLH after vaccination in
melanoma patients[44]. According to previous work[45], PDC did
not take up cellular material from live, apoptotic, or necrotic B
cells even though they expressed CD36 and low levels of avb5, two
receptors involved in the capture of dying cells. This was in
contrast with MoDC, which efficiently endocytosed B-cell derived
material from all the different sources of B cells. This phenomenon
may be due to the expression of more diverse endocytic receptors
on MoDC allowing them to capture apoptotic or necrotic cells
(CD91, CD36, avb3, avb5), opsonized cells (CD16 or CD32), or
Figure 3. Measurement of soluble or cellular antigens uptake by flow cytometry. (A) Endocytosis of soluble tracers. MoDC, purified BDCA-
4+ primary PDC or GEN3 cells were incubated for 2 hours at 4uC (filled curves) or 37uC (open curves) with Ovalbumin, Lucifer yellow and Dextran.
Mean fluorescence intensity (MFI) values are indicated. Results are representative of two experiments. (B) Uptake of cellular material. PKH26-stained B
cells were induced into apoptosis, necrosis, or were opsonized with CD20 mAb Rituximab or left untreated. They were then incubated with MoDC or
GEN3 for 2 hours and stained as described in materials and methods section. PKH26 fluorescence, measuring cellular material uptake, was analyzed
gating on MoDC (CD11b
pos) or GEN3 (CD4
posCD36
pos) not involved in cell conjugates (CD19
negCD20
neg). Percentages of positive cells at 37uC (open
curves), relative to incubation at 4uC (filled curves) are indicated. These data are representative of two independent experiments.
doi:10.1371/journal.pone.0007111.g003
PDC Cross-Present Viral Ag
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[46–48]. Altogether, MoDC are undoubtedly more efficient than
PDC at endocytosing cells.
Interestingly, our results show an efficient transfer of cellular
material from influenza-treated B cells (flu-B cells) to PDC, in an
actin and Ca
2+ dependent manner. We documented this uptake by
fluorescence microscopy, and found that most PDC contained
fragments of virus-treated cells. The functional consequences of
this endocytosis by PDC were then examined. Upon exposure to
flu-B cells of GEN3 or primary PDC secreted IFNa and matured,
as evidenced by acquisition of costimulatory molecules. The up-
regulation of CCR7 suggests that after the encounter with infected
cells in periphery, and capture of cell-derived antigenic material,
PDC could traffic to T cell zones in the lymph nodes and present
acquired antigens. Furthermore, our study provides further
evidence that following uptake and maturation, PDC are able to
cross-present viral antigens captured from virus-exposed cells to
specific T cells. The first demonstration of the ability of PDC to
cross-present viral antigens taken from infected cells was recently
performed by Hoeffel at Al[49], in a model where PDC cross-
Figure 4. PDC internalized cellular material from influenza-treated B cells. (A and B) measurement of influenza-treated B cells uptake by
flow cytometry. B cells (B1 and B2) were stained with PKH26, exposed (lower panels) or not (upper panels) to virus for 18 hours, extensively washed
and then incubated with purified PDC or GEN3 for 2 hours at 4uC (filled curves) or 37uC (open curves). PKH26 fluorescence was evaluated as in
Figure 3, gating on primary PDC and GEN3 not involved in conjugates with B cells. As control, GEN3 were also incubated following the same
procedure for two hours with the supernatant of 18-hour flu-B cell culture (SN-B2). (C) Fluorescence microscopy imaging of B cell material by GEN3.
PKH26+ flu-B cells appear yellow and GEN3 were stained in green with FITC-conjugated CD4 and CD36. (D) Membrane capture is Ca
2+and actin-
dependent. Cellular uptake was measured as described in Fig. 3A, at 4uC (open curves) or 37uC (filled curves) in the presence or absence of EDTA or
cytochalasin D (CDD). (E) Maturation down-regulated cell capture by PDC. GEN3 were matured in presence of CpG for 24 h (lower panel) or not
(upper panel) and incubated with B cells exposed (open curves) or not (filled curves) to virus for 18 hours.
doi:10.1371/journal.pone.0007111.g004
PDC Cross-Present Viral Ag
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infected cells. This mechanism reveals a highly relevant role for
PDC in eliciting anti-viral immune responses. Indeed, during a
natural infection, DC are not necessarily the primary infected cells,
and admittedly virally infected non-APC are unable to stimulate
CD8+ T cell immunity. Moreover, many viruses such as HIV,
measles virus or HCMV infect DC, and have evolved mechanisms
to subvert DC function, by disturbing their maturation or ability to
secrete cytokines[50–52]. Here, by their ability to engulf viral
antigens from virus-containing cells without being themselves
infected, PDC could acquire and present viral antigens, avoiding
virus-induced subversion of their functions.
Our results show that after capture, viral-antigens are processed
and presented into the MHC class I pathway. How do PDC detect
the infection, and acquire cell-derived fragments? Among flu-B
cells, some died in vitro, however, in our hands PDC engulfed
neither necrotic nor apoptotic cells (our data and [45]). Therefore,
recognition of influenza-treated living cells by PDC likely did not
rely on dead cell capture, contrary to the model recently described
in MoDC by Frleta et Al [53]. Flu-B cells expressed viral
hemagglutinin on the B cell surface (data not shown), a molecule
that could allow PDC recognition of virus-treated cells. A potential
receptor is NKp44, which recognizes influenza hemagglutinin[54],
but it is expressed on PDC only after activation[55]. Since mature
Figure 5. Activation of PDC upon exposure to flu-B cells. (A) In upper panels, GEN3 or purified PDC were incubated (open curves) or not (filled
curves) with influenza virus for 24 hours, as positive control of their maturation, and cells were stained with indicated mAb. In lower panels, B cells
were exposed (open curves) or not (filled curves) to virus for 18 hours, washed, and then incubated with GEN3 or purified PDC. After a 24-hour co-
culture, cells were stained with indicated mAb, and maturation was assessed by flow cytometry after gating on GEN3 cells (according to their FSC/SSC
profile) or on BDCA2
pos BDCA4
pos PDC. Data are representative of two independent experiments. (B) GEN3 or purified PDC were incubated with or
without influenza virus, B cells or Flu-B cells for 24 hours, and then IFNa levels in supernatants were measured by ELISA. Data represent mean6SD of
2 experiments performed in duplicates.
doi:10.1371/journal.pone.0007111.g005
PDC Cross-Present Viral Ag
PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e7111GEN3 lost their endocytic capacity, the receptor involved is likely
down regulated during PDC maturation. Further studies are
required to determine whether the recognition of infected cells by
PDC relies on virus- or endogenous cell-derived signals, and what
kind of receptor on PDC is involved.
The efficiency with which viral antigens from flu-B cells were
cross-presented may be due to the high efficiency of their uptake
by PDC. It is also possible that IFNa secreted by PDC in
association with other unknown factors may enhance the cross-
presentation of internalized antigens[23], through a still undeter-
mined mechanism. IFN-b, not measured in our study, could also
be involved, as this pro-inflammatory cytokine secreted by various
kinds of infected cells has been described to prime DC, enhancing
their activation in response to influenza virus[56]. Alternatively,
engagement of TLR (likely TLR7, expressed by PDC[57] and
involved in influenza virus recognition[5]) on PDC may influence
phagosome maturation in PDC [58], and favor the generation of
viral peptides for cross-presentation. Whatever the mechanism,
cross-presentation of viral antigens was at least as efficient as direct
presentation by PDC exposed to influenza virus.
In conclusion, our study identifies a role for PDC as a central
professional APC during viral infections, by being extremely
sensitive not only to direct viral exposure, but also to infection of
bystander cells. We suggest that PDC play a major role in the
control of viral infection through IFNa secretion and TRAIL
expression during the innate phase of immune response, and by
the further activation CD8+ T cell adaptive immunity through
cross-presentation of viral derived antigens captured from infected
cells. Thus, the role of PDC as a major link between innate and
adaptive immunity is further emphasized.
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